This House Resolution designates April 5, 2025 as Barth Syndrome Awareness Day and expresses the House’s support for awareness, earlier diagnosis, and ongoing research into Barth syndrome and other ultrarare diseases. It notes the roles of patient advocacy groups and medical centers in education and care, and it references the lack of FDA-approved therapies and the importance of regulatory pathways that support rare-disease development.
The resolution is a formal, non-binding statement of congressional regard rather than a funding or regulatory mandate.
At a Glance
What It Does
Designates April 5, 2025 as Barth Syndrome Awareness Day and expresses support for awareness, diagnosis, research, and regulatory pathways related to Barth syndrome and ultrarare diseases.
Who It Affects
Patients and families affected by Barth syndrome, along with clinicians across multidisciplinary teams and organizations focused on rare diseases.
Why It Matters
Raising public awareness can mobilize advocacy, improve early diagnosis, and encourage research without creating new regulatory duties or funding obligations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Barth syndrome is a rare, genetic disorder that affects multiple body systems and can be life-threatening in childhood. This resolution does not change any laws or create new programs.
Instead, it designates a specific day—April 5, 2025—as Barth Syndrome Awareness Day, signaling a national commitment to awareness, education, and collaboration among patients, clinicians, researchers, and advocacy groups. The bill cites the Barth Syndrome Foundation and Kennedy Krieger Institute as key actors in awareness, diagnosis, and care, and it notes that no FDA-approved treatment currently exists while underscoring the need for ongoing research and development in rare-disease therapeutics and regulatory pathways that support ultrarare diseases.
The resolution aligns with broader historical policy contexts that support orphan-disease research and patient-centered drug development but does not authorize funding or impose new regulatory requirements.
The Five Things You Need to Know
The bill designates April 5, 2025 as Barth Syndrome Awareness Day.
It notes that Barth syndrome is a rare, multi-system genetic disorder with limited diagnosed cases.
The resolution references the Barth Syndrome Foundation and Kennedy Krieger Institute as central to awareness and care.
It acknowledges there is no FDA-approved treatment for Barth syndrome and calls for ongoing research and regulatory pathways.
There are no new funding commitments, mandates, or regulatory requirements created by the measure.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Designation of Barth Syndrome Awareness Day
The resolution designates a specific observance, April 5, 2025, as Barth Syndrome Awareness Day in the United States. This section establishes the symbolic act and frames it as a focal point for education, outreach, and public interest in Barth syndrome.
Rationale and Background
This section grounds the designation in the medical and policy context: Barth syndrome is a rare genetic disorder caused by TAFAZZIN mutations, with multisystem involvement and historically limited treatment options. The text underscores the challenges of diagnosis and access to specialized care and situates the designation within a broader policy landscape that has supported orphan-disease research and accelerated drug development pathways.
Role of Key Organizations and Policy Context
The resolution highlights the Barth Syndrome Foundation and Kennedy Krieger Institute as leading actors in awareness, education, and care delivery. It also situates Barth syndrome within the policy framework created by programs like the Orphan Drug Act and FDA Accelerated Approval Pathway, which have historically advanced treatment development for rare diseases.
Scope, Limitations, and Implications
As a non-binding, symbolic measure, the resolution does not authorize funding or impose regulatory obligations. It signals congressional support and the potential for future advocacy and policy conversations focused on improving diagnosis, care, and research for Barth syndrome and other ultrarare diseases.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Barth syndrome patients and their families, who gain heightened awareness and potential for improved access to information and services.
- Barth Syndrome Foundation, which may see increased visibility and opportunities to advance education and fundraising.
- Kennedy Krieger Institute’s Barth Syndrome Clinic and related clinicians, benefiting from broader recognition of the need for multidisciplinary care.
- Researchers and clinicians focused on Barth syndrome and ultrarare diseases, who may experience increased attention and collaboration opportunities.
- Advocacy groups and patient communities that rely on public awareness to drive research and support.
Who Bears the Cost
- No new funding is authorized by this measure, so there are no explicit fiscal costs assigned to taxpayers.
- House staff and committee staff may incur minimal time to process commemorative activities and public messaging.
- Healthcare providers and institutions are not obligated to implement new requirements; any activities would be voluntary advocacy or awareness efforts rather than mandated changes.
- Advocacy organizations may incur costs if they choose to pursue additional awareness campaigns, but these are not mandated by the resolution.
Key Issues
The Core Tension
Symbolic recognition versus material policy action: the bill raises awareness and signals support, but it does not itself fund or mandate programs. The tension is between using a day to catalyze substantive outcomes (improved diagnosis, treatment development) and risk of treating the designation as an end in itself without clear mechanisms for follow-on action.
Because this is a symbolic resolution, it does not mandate actions, allocate funds, or impose regulatory duties. Its value lies in elevating Barth syndrome on the national stage, which can catalyze education, patient advocacy, and collaboration across clinicians, researchers, and policymakers.
The central policy question is whether a nationally observed awareness day can translate into tangible improvements in diagnosis, access to care, and research investment for ultrarare diseases, without diverting attention or resources from other conditions. The measure relies on voluntary participation by organizations, clinicians, and the public to maximize its impact.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.